NAYA Biosciences Inc
NASDAQ:NAYA
NAYA Biosciences Inc
Other Assets
NAYA Biosciences Inc
Other Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NAYA Biosciences Inc
NASDAQ:NAYA
|
Other Assets
$5.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Other Assets
$36.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
42%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Other Assets
$17.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Stryker Corp
NYSE:SYK
|
Other Assets
$15.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Other Assets
$23.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Other Assets
$347.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
See Also
What is NAYA Biosciences Inc's Other Assets?
Other Assets
5.9m
USD
Based on the financial report for Sep 30, 2024, NAYA Biosciences Inc's Other Assets amounts to 5.9m USD.
What is NAYA Biosciences Inc's Other Assets growth rate?
Other Assets CAGR 1Y
-28%
Over the last year, the Other Assets growth was -28%.
You don't have any saved screeners yet